BEUDAMED
    FDA Adverse Event Death Summary report: N

    EUFLEXXA 20 MG/2ML (6=3 SYR)

    MDR report key: 24790187 · Received April 6, 2026

    Report

    Report Number
    MW5186362
    Event Type
    Death
    Date Received
    April 6, 2026
    Date of Event
    December 24, 2025
    Report Date
    February 12, 2026
    Manufacturer
    FERRING PHARMACEUTICALS, INC.
    Product Code
    MOZ
    Adverse Event
    Yes
    Report Source
    Voluntary report
    Reporter Location
    PA, US
    Reporter Occupation
    003
    Health Professional
    N

    Narratives

    Description of Event or Problem · 0

    EVENT: (B)(6), FAMILY MEMBER, REPORTS THE PATIENT HAS BEEN DECEASED SINCE (B)(6) 2025. NO ADDITIONAL DETAILS REPORTED. FREQ: INJECT 1 SYRINGE INTRA-ARTICULARLY INTO EACH KNEE ONCE WEEKLY FOR 3 WEEKS. DIAGNOSIS FOR USE: BILATERAL PRIMARY OSTEOARTHRITIS OF KNEE. THERAPY DATES: (B)(6) 2025.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    849720 EUFLEXXA 20 MG/2ML (6=3 SYR) ACID, HYALURONIC, INTRAARTICULAR MOZ FERRING PHARMACEUTICALS, INC. Y10917A

    Patients

    Seq Age Sex Outcome Treatment
    1 82 YR Male Death